JPWO2021155243A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021155243A5 JPWO2021155243A5 JP2022546537A JP2022546537A JPWO2021155243A5 JP WO2021155243 A5 JPWO2021155243 A5 JP WO2021155243A5 JP 2022546537 A JP2022546537 A JP 2022546537A JP 2022546537 A JP2022546537 A JP 2022546537A JP WO2021155243 A5 JPWO2021155243 A5 JP WO2021155243A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- lipid
- hrsv
- composition according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000711920 Human orthopneumovirus Species 0.000 claims 9
- 150000002632 lipids Chemical class 0.000 claims 9
- 102000003886 Glycoproteins Human genes 0.000 claims 5
- 108090000288 Glycoproteins Proteins 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- -1 cationic lipid Chemical class 0.000 claims 4
- 210000005220 cytoplasmic tail Anatomy 0.000 claims 4
- 229930182558 Sterol Natural products 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- 230000007935 neutral effect Effects 0.000 claims 3
- 150000003432 sterols Chemical class 0.000 claims 3
- 235000003702 sterols Nutrition 0.000 claims 3
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 2
- 108700026244 Open Reading Frames Proteins 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 238000007385 chemical modification Methods 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- JFBCSFJKETUREV-LJAQVGFWSA-N 1,2-ditetradecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCCCC JFBCSFJKETUREV-LJAQVGFWSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims 1
- UVBYMVOUBXYSFV-UHFFFAOYSA-N 1-methylpseudouridine Natural products O=C1NC(=O)N(C)C=C1C1C(O)C(O)C(CO)O1 UVBYMVOUBXYSFV-UHFFFAOYSA-N 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 230000005875 antibody response Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 1
- 229940029575 guanosine Drugs 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229920002477 rna polymer Polymers 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062967888P | 2020-01-30 | 2020-01-30 | |
| US62/967,888 | 2020-01-30 | ||
| PCT/US2021/015840 WO2021155243A1 (en) | 2020-01-30 | 2021-01-29 | Respiratory virus immunizing compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023513073A JP2023513073A (ja) | 2023-03-30 |
| JPWO2021155243A5 true JPWO2021155243A5 (https=) | 2024-07-01 |
| JP2023513073A5 JP2023513073A5 (https=) | 2024-07-01 |
Family
ID=77079256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546537A Pending JP2023513073A (ja) | 2020-01-30 | 2021-01-29 | 呼吸器系ウイルス免疫化組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230338506A1 (https=) |
| EP (1) | EP4096683A4 (https=) |
| JP (1) | JP2023513073A (https=) |
| KR (1) | KR20220133911A (https=) |
| CN (1) | CN115103682A (https=) |
| AU (1) | AU2021214774A1 (https=) |
| BR (1) | BR112022015053A2 (https=) |
| CA (1) | CA3169664A1 (https=) |
| IL (1) | IL295148A (https=) |
| MX (1) | MX2022009429A (https=) |
| WO (1) | WO2021155243A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| TW201729835A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道病毒疫苗 |
| HRP20220652T1 (hr) | 2015-12-10 | 2022-06-24 | Modernatx, Inc. | Pripravci i postupci unosa terapijskih sredstava |
| MA45052A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
| CN116837052A (zh) | 2016-09-14 | 2023-10-03 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
| MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| WO2018089851A2 (en) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Influenza vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS Vaccine |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
| WO2018187590A1 (en) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
| ES2983060T3 (es) | 2017-08-18 | 2024-10-21 | Modernatx Inc | Variantes de ARN polimerasa |
| WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| MA53650A (fr) | 2018-09-19 | 2021-07-28 | Modernatx Inc | Lipides peg et leurs utilisations |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| CN113795579A (zh) | 2019-02-20 | 2021-12-14 | 摩登纳特斯有限公司 | 用于共转录加帽的rna聚合酶变体 |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| CA3132975A1 (en) | 2019-03-11 | 2020-09-17 | Modernatx, Inc. | Fed-batch in vitro transcription process |
| EP3938379A4 (en) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | Hiv rna vaccines |
| EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2022099003A1 (en) | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| WO2022221336A1 (en) * | 2021-04-13 | 2022-10-20 | Modernatx, Inc. | Respiratory syncytial virus mrna vaccines |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| IL320459A (en) * | 2022-10-27 | 2025-06-01 | Pfizer | Rna molecules encoding rsv-f and vaccines containing them |
| WO2024193965A1 (en) * | 2023-03-17 | 2024-09-26 | Glaxosmithkline Biologicals Sa | Rsv-f-encoding nucleic acids |
| CN118108812B (zh) * | 2023-05-04 | 2025-04-15 | 国药中生生物技术研究院有限公司 | Rsv f蛋白的突变体 |
| US20250009865A1 (en) * | 2023-05-10 | 2025-01-09 | Sanofi | Combination respiratory mrna vaccines |
| AU2024314167A1 (en) * | 2023-06-21 | 2026-02-05 | Shenzhen Shenxin Biotechnology Co., Ltd. | Respiratory syncytial virus (rsv) vaccine |
| CN119979573A (zh) * | 2023-11-03 | 2025-05-13 | 纳美信(上海)生物科技有限公司 | 一种呼吸道合胞病毒mRNA疫苗 |
| CN117586359A (zh) * | 2024-01-19 | 2024-02-23 | 北京安百胜生物科技有限公司 | 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽 |
| CN118064456B (zh) * | 2024-03-01 | 2024-10-29 | 嘉译生物医药(杭州)有限公司 | 一种针对人合胞病毒的新型的RSV B mRNA疫苗 |
| WO2025250938A2 (en) | 2024-05-31 | 2025-12-04 | Modernatx, Inc. | Respiratory syncytial virus and metapneumovirus vaccines |
| CN121620537A (zh) * | 2024-06-19 | 2026-03-06 | 厦门万泰沧海生物技术有限公司 | Rsv和hmpv融合f蛋白及其用途 |
| CN118480560B (zh) * | 2024-07-09 | 2024-11-26 | 北京悦康科创医药科技股份有限公司 | 呼吸道合胞病毒mRNA疫苗及其制备方法和应用 |
| CN120118162B (zh) * | 2025-03-07 | 2026-03-10 | 深圳华大火眼工程科技有限公司 | 一种呼吸道合胞病毒的f蛋白突变体、其组合及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010264686A1 (en) * | 2009-06-24 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Vaccine |
| FI2970398T3 (fi) * | 2013-03-13 | 2024-08-06 | Us Health | Rsv f -prefuusioproteiineja ja niiden käyttö |
| MX2018004917A (es) * | 2015-10-22 | 2019-04-01 | Modernatx Inc | Vacuna de virus sincitial respiratorio. |
| TW201729835A (zh) * | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道病毒疫苗 |
| US11174292B2 (en) * | 2016-03-29 | 2021-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Substitutions-modified prefusion RSV F proteins and their use |
| WO2018089851A2 (en) * | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Influenza vaccine |
| WO2018107088A2 (en) * | 2016-12-08 | 2018-06-14 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| EP3595713A4 (en) * | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS Vaccine |
| KR102774312B1 (ko) * | 2017-04-04 | 2025-03-05 | 유니버시티 오브 워싱톤 | 파라믹소바이러스 및/또는 뉴모바이러스 f 단백질을 표시하는 자가-조립 단백질 나노구조체 및 이의 용도 |
| WO2019148101A1 (en) * | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| CA3091558A1 (en) * | 2018-04-17 | 2019-10-24 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
-
2021
- 2021-01-29 CN CN202180011671.6A patent/CN115103682A/zh active Pending
- 2021-01-29 EP EP21747384.2A patent/EP4096683A4/en active Pending
- 2021-01-29 AU AU2021214774A patent/AU2021214774A1/en not_active Abandoned
- 2021-01-29 MX MX2022009429A patent/MX2022009429A/es unknown
- 2021-01-29 US US17/796,401 patent/US20230338506A1/en active Pending
- 2021-01-29 IL IL295148A patent/IL295148A/en unknown
- 2021-01-29 KR KR1020227028349A patent/KR20220133911A/ko not_active Withdrawn
- 2021-01-29 BR BR112022015053A patent/BR112022015053A2/pt not_active Application Discontinuation
- 2021-01-29 JP JP2022546537A patent/JP2023513073A/ja active Pending
- 2021-01-29 CA CA3169664A patent/CA3169664A1/en active Pending
- 2021-01-29 WO PCT/US2021/015840 patent/WO2021155243A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021155243A5 (https=) | ||
| JPWO2022155530A5 (https=) | ||
| JPWO2022155524A5 (https=) | ||
| JP2023164537A5 (https=) | ||
| JPWO2022221440A5 (https=) | ||
| CA3236924A1 (en) | Respiratory syncytial virus rna vaccine | |
| US9125870B2 (en) | Vaccine against RSV | |
| BR112014023196B1 (pt) | Vacinas contra o vírus sincicial respiratório (rsv), seu método de produção, e ácido nucleico recombinante isolado | |
| WO1999008706A1 (en) | Recombinant porcine adenovirus vector | |
| JP2007503379A5 (https=) | ||
| CN118084714B (zh) | 一种脂质化合物、包含其的脂质纳米颗粒及其应用 | |
| CN116808191A (zh) | 新型冠状病毒疫苗及其制备方法和应用 | |
| EP1844007A1 (en) | Use of aminodithiol as a reducing agent for hair perming | |
| García‐Salcedo et al. | Molecular characterization and transcription of the histone H2B gene from the protozoan parasite Trypanosoma cruzi | |
| JPWO2021251453A5 (https=) | ||
| JPH0217538B2 (https=) | ||
| Payette et al. | Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanisms | |
| JPWO2023091490A5 (https=) | ||
| JPH01153667A (ja) | 置換ジカルボン酸−ビス（３，５，−ジカルバモイル−２，４，６，−トリヨード−アニリド）、その製法およびこの化合物を含有するレントゲン造影剤 | |
| JPWO2023102373A5 (https=) | ||
| TW202516013A (zh) | 呼吸道融合病毒（ｒｓｖ）疫苗 | |
| CN1646079A (zh) | 毛发化妆品 | |
| JPWO2023069498A5 (https=) | ||
| Masiga et al. | Some evidence of an age susceptibility to contagious bovine pleuropneumonia | |
| JP4271424B2 (ja) | トキソプラズマ症に対する遺伝子ワクチン及びそれを用いたトキソプラズマ症の予防方法 |